CHONGQING, CHINA - OCTOBER 27: The Pfizer logo is displayed on a smartphone screen in front of a ... [+] larger Pfizer logo on October 27, 2024 in Chongqing, China. (Photo by Cheng Xin/Getty Images) Getty Images Pfizer stock (NYSE: PFE) is down 7% in a month, amid rising concerns over the future of vaccines under Robert F. Kennedy Jr. in the new government, given the perception of him being a prominent anti-vaccine activist. Pfizer has had its own issues with falling Covid-19 vaccine sales weighing on its s ...

Goldman Sachs hosted a meeting with Pfizer Inc's PFE newly appointed Chief Scientific Officer Chris Boshoff (effective January 1, 2025). The analyst maintains the Buy rating with a price target of $33. When discussing core capabilities at Pfizer, the commentary highlighted a strategic shift toward prioritizing efforts. The focus will be on opportunities expected to deliver the highest economic returns while maintaining a balanced portfolio of high-risk and low-risk projects. With an annual R&D budget of abo ...

Despite Pfizer's (PFE 0.23%) recent struggles with falling earnings and a bid by an activist investor to unseat its leadership, the pharma juggernaut is still actively advancing its core priorities and giving investors plenty of reasons to consider buying its stock while it's cheap. With that in mind, here's one new initiative that's worth thinking about if you're wondering about whether to make an investment. This new play could lead to super-effective medicines down the line On Nov. 20, Pfizer announced t ...

Leading vaccine makers like Eli Lilly and Co. NYSE: LLY, Pfizer Inc. NYSE: PFE, and AstraZeneca plc NASDAQ: AZN may have faded from the spotlight since the peak of the COVID-19 pandemic, but now there is reason to expect renewed interest. As investors look ahead to the second Trump administration, the incoming president's nomination of outspoken vaccine critic Robert F. Kennedy Jr. to the position of U.S. Secretary of Health and Human Services has refocused attention on the future of these companies and the ...

One stock that just can't seem to catch a break of late is Pfizer (PFE 0.23%). Even though it posted some decent earnings numbers, investors can't shake the fear that the business is facing daunting headwinds that could send its $145 billion valuation lower in the months and years ahead. And while the markets have done well overall, shares of Pfizer are down some 11% this year. Is the healthcare stock in big trouble and headed for a greater decline, or are investors perhaps a bit too bearish on the business ...

The last time I wrote, I was having a hard time finding value in the high-quality dividend growth segment that I invest in. I'm happy to report that this time around, there are several stocks that potentially appear toWhy DividendRodeo? It's not the wild ride that investing sometimes provides that I'm addicted to, it's that rush that an ever-increasing flow of passive income provides. I do not have a financial background - my background is actually engineering - but I have been a self-directed investor for ...

Nobody can predict the future, but it's not hard to imagine increasing pharmaceutical sales. In 2022, prescription drug spending in the U.S. climbed more than 8% to reach $406 billion. It's a lot but still less than one-third of the amount soaked up by American hospitals. It might not feel like it when you pay the bill, but prescription drugs give healthcare systems a tremendous return on their investment. With this in mind, it's no wonder billionaires are buying up shares of one of America's largest pharma ...

Summary of Pfizer Inc. Conference Call Company Overview - **Company**: Pfizer Inc. (NYSE:PFE) - **Event**: Jefferies London Healthcare Conference - **Date**: November 20, 2024 Key Points Industry and Market Context - Pfizer is focused on execution and enhancing its Oncology franchise while optimizing its cost structure post-COVID, with a revenue base of approximately $60 billion [4][3] - The company is navigating changes in the U.S. healthcare administration, which may have both positive and negative impacts on its business [6][7][8] Financial Performance and Guidance - Pfizer's revenue guidance for 2023 was significantly revised down from $50 billion to $20 billion due to COVID-related impacts, ultimately yielding just over $12 billion [24][25] - The company anticipates a more stable revenue trajectory moving into 2024, with COVID franchise revenues expected to stabilize around $10 billion [25][26] - Pfizer is tracking well for the current year, although the RSV market has contracted to about 60% of last year's size [28] Cost Management - Pfizer has announced $5.5 billion in cost cuts, with ongoing efforts to optimize costs in R&D, SG&A, and COGS [29][30] - The company is focused on ensuring that investments in new products make economic sense and align with long-term growth strategies [22][30] Product Pipeline and Development - Pfizer is preparing for a significant update on its obesity drug, danuglipron, in Q1 2025, with expectations of competitive weight loss data [11][12][19] - The company is optimistic about its Oncology pipeline, particularly with CDK4/6 inhibitors and other small molecules, which are expected to dominate the market for HR-positive breast cancer [40][44] - Pfizer is exploring the potential of combining its HER2 ADC with PD-1 therapies, anticipating positive outcomes in Phase 3 trials [60][63] Regulatory and Legislative Impact - The company plans to provide guidance for 2025 that includes the impact of the Inflation Reduction Act and Medicare Part D reform, which may have both positive and negative effects on revenue [52][53] - There is an expectation that the reforms will support medication adherence but may also lead to revenue headwinds for high-priced drugs [53][54] Strategic Considerations - Pfizer is evaluating its asset portfolio for potential divestments, particularly in light of its recent acquisition of Seagen and ongoing efforts to improve its balance sheet [56][58] - The company is committed to maximizing shareholder value by focusing on economically viable products and strategic partnerships in R&D [38][58] Management Insights - Andrew Baum highlighted the strengths of Pfizer's medicinal chemistry and execution capabilities, emphasizing the need to focus on products that deliver meaningful economic returns [34][36] - The management team is dedicated to ensuring that the company's powerful resources are directed towards high-value projects that benefit both shareholders and patients [38][39] Additional Insights - The management expressed confidence in the global market potential for obesity treatments, indicating a significant opportunity beyond the U.S. [17][18] - There is a recognition of the competitive landscape in Oncology, with a focus on maintaining a leading position through innovative therapies and strategic development [41][44] This summary encapsulates the key discussions and insights from the Pfizer conference call, highlighting the company's strategic direction, financial outlook, and product development initiatives.

In my previous and first article about Pfizer Inc. (NYSE: PFE ), I argued that the stock could be a bargain. In the meantime, the stock increased a little bit, but especially in the last few days, it declined again and is now tradingMy analysis is focused on high-quality companies, that can outperform the market over the long-run due to a competitive advantage (economic moat) and high levels of defensibility. Focused on European and North American companies, but without constraints regarding market capitali ...

Pfizer (PFE) announced that the European Commission (“EC”) has granted marketing authorization for Hympavzi (marstacimab) to treat certain hemophilia patients.With this nod, the once-weekly Hympavzi gets approved for routine prophylaxis (RP) to prevent or reduce the frequency of bleeding episodes in patients aged 12 years and older with hemophilia A or B, without inhibitors to Factor VIII (FVIII) or Factor IX (FIX). Following this approval, Hympavzi became the first hemophilia medicine approved in the Unite ...